Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: XENICAL

« Back to Dashboard

Xenical is a drug marketed by Hoffmann La Roche and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug.

The generic ingredient in XENICAL is orlistat. There are nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the orlistat profile page.

Summary for Tradename: XENICAL

Patents:1
Applicants:1
NDAs:1
Suppliers: see list2

Pharmacology for Tradename: XENICAL

Clinical Trials for: XENICAL

Study of Fat Malabsorption by Lipiblock Versus Xenical
Status: Completed Condition: Obesity

Meta-analysis of Orlistat Laboratory Data From Placebo-controlled Clinical Trials
Status: Completed Condition: Obesity

Orlistat Induced Modulation on the Fatty Acid Composition in Obese Females
Status: Completed Condition: Overweight

Adding Guided Self-Help Group Therapy to the Alli Weight Loss Program in Treating Binge Eating Disorder
Status: Completed Condition: Overweight; Eating Disorders

Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus
Status: Completed Condition: Fatty Liver; Hepatitis C

Risk Management Plan (RMP) Survey for Purchasers of AlliĀ® (60 mg Orlistat) in the European Union.
Status: Not yet recruiting Condition: Weight Loss

Metformin Versus Orlistat in Obese Polycystic Ovary Syndrome (PCOS) Patients
Status: Completed Condition: Obesity

Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases
Status: Completed Condition: Diabetes Mellitus; Hypertension; Metabolic Disease; Obesity; Sleep Apnea Syndrome

A Low-Carbohydrate, Ketogenic Diet Versus Orlistat for Weight Loss
Status: Completed Condition: Diabetes Mellitus; Obesity

Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia
Status: Not yet recruiting Condition: Type 1 Hyperlipoproteinemia

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hoffmann La Roche
XENICAL
orlistat
CAPSULE;ORAL020766Apr 23, 1999RXYes6,004,996*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc